Skip to main content

Table 2 Number (Percentage) of patients gaining or losing ETDRS letters at different visits (FAS Population)

From: Sub-optimal gain in vision in retinal vein occlusion due to under-treatment in the real world: results from an open-label prospective study of Intravitreal Ranibizumab

Number of patients gaining ETDRS letters, n (%)

Number of patients losing ETDRS letters, n (%)

 

Week 12(N = 86)

Week 24(N = 72)

Week 48(N = 65)

 

Week 12(N = 86)

Week 24(N = 72)

Week 48(N = 65)

Gain

> = 0

72 (83.7)

57 (79.2)

53 (81.5)

Loss

> = 0

27 (31.4)

20 (27.8)

22 (33.8)

Gain

> = 5

55 (64.0)

49 (68.1)

40 (61.5)

Loss

> = 5

13 (15.1)

14 (19.4)

12 (18.5)

Gain

> = 10

32 (37.2)

32 (44.4)

29 (44.6)

Loss

> = 10

8 (9.3)

12 (16.7)

9 (13.8)

Gain

> = 15

28 (32.6)

31 (43.1)

28 (43.1)

Loss

> = 15

8 (9.3)

11 (15.3)

6 (9.2)

  1. Percentage was calculated using “N” at each visit; N Total number of patients in full analysis set at each visit; n Number of patients with gaining or losing ETDRS Letters;
  2. ETDRS Early Treatment Diabetic Retinopathy Scale